ERBB2 and breast carcinoma: Secondly, trastuzumab inhibition of HER2 possibly exerts a distinct effect as compared to endogenous knockdown of HER2 since trastuzumab was previously confirmed to enhance HER2 phosphorylation at specific phosphotyrosine sites in trastuzumab-sensitive breast cancer cells [66–68].